Literature DB >> 10047468

Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1.

R S Li1, G L Law, R A Seifert, P J Romaniuk, D R Morris.   

Abstract

The product of the Wilm's tumor suppressor gene, WT1, is a zinc-finger DNA-binding protein, which is thought to be a transcription factor. Two genes, those encoding epidermal growth factor receptor and syndecan-1, are known to be endogenous targets of WT1. Previous studies had identified binding sites for WT1 in the promoter of the ornithine decarboxylase (ODC) gene. In this paper, we tested whether the endogenous ODC gene might be a target of WT1 by establishing lines of baby hamster kidney (BHK) cells that expressed WT1 isoform A under control of a tetracycline-regulated expression system. When expression of WT1 was activated in BHK cells, the cellular level of ODC mRNA declined, with kinetics that correlated with the increase in WT1 level, demonstrating that the endogenous ODC gene was indeed responsive to cellular level of WT1. WT1 isoforms A and B inhibited the activity of the ODC promoter by approximately fivefold in transiently transfected BHK cells, while isoforms C and D, which have altered DNA binding domains, had no significant effect. The sequence CTCCCCCGC, located at nucleotides -106 to -98 relative to the site of transcriptional initiation in the ODC gene, interacted with the zinc-finger domain of isoforms A and B of WT1 with high affinity and specificity. A mutation in the binding site that disrupted this interaction partially removed the inhibition of ODC promoter activity by WT1, as did mutation of the two E-box sequences in intron I of the ODC gene. Simultaneous mutation of the WT1-binding motif and the two E-boxes completely abolished inhibition by WT1 of ODC promoter activity. These results, taken together, implicate the ODC gene as a downstream target of the tumor suppressor WT1. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047468     DOI: 10.1006/excr.1998.4361

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  Overexpression of antizyme in the hearts of transgenic mice prevents the isoprenaline-induced increase in cardiac ornithine decarboxylase activity and polyamines, but does not prevent cardiac hypertrophy.

Authors:  C A Mackintosh; D J Feith; L M Shantz; A E Pegg
Journal:  Biochem J       Date:  2000-09-15       Impact factor: 3.857

3.  Regulation of all members of the antizyme family by antizyme inhibitor.

Authors:  Ursula Mangold; Ekkehard Leberer
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

4.  Amine oxidase copper-containing 1 (AOC1) is a downstream target gene of the Wilms tumor protein, WT1, during kidney development.

Authors:  Karin M Kirschner; Julian F W Braun; Charlotte L Jacobi; Lucas J Rudigier; Anja Bondke Persson; Holger Scholz
Journal:  J Biol Chem       Date:  2014-07-17       Impact factor: 5.157

5.  The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy.

Authors:  Lesley A Simpson; Emily A Burwell; Kida A Thompson; Samira Shahnaz; Allen R Chen; David M Loeb
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

6.  Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells.

Authors:  Lihua Chen; Günter Daum; Kanchan Chitaley; Scott A Coats; Daniel F Bowen-Pope; Martin Eigenthaler; Naresh R Thumati; Ulrich Walter; Alexander W Clowes
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-06-03       Impact factor: 8.311

Review 7.  Cancer immunotherapy targeting WT1 protein.

Authors:  Haruo Sugiyama
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.

Authors:  E Ann Hudson; Lynne M Howells; Barbara Gallacher-Horley; Louise H Fox; Andreas Gescher; Margaret M Manson
Journal:  BMC Cancer       Date:  2003-01-14       Impact factor: 4.430

9.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.